

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- Latinx oncology leaders talk about the impact of federal policy on cancer outcomes in Latinx communities
- Why both somatic and germline genomic profiling are essential for precision oncology